Cairo, Egypt: Head of the clinical trials team for the Egyptian vaccine Osama Azmy on Sunday, February 6, 2022, underscored that the first-ever COVID-19 vaccine produced by Egypt – COVI-VAX had shown quite sound results in its clinical trials.
He stated, “Good news” about the Egyptian vaccine will be heard “very soon“, adding that the healthcare professionals of the middle east country are also working on the other Egyptian coronavirus drug, which is considered a “food supplement”.
He added that this supplement would work for curing and preventing the novel coronavirus. The trials for the COVI-VAX began in the month of November 2021. In the initial days, it was announced that the clinical trials for the Egyptian vaccine would take around six to nine months.
The Egyptian Drug Authority (EDA) stated that COVI-VAX is an outcome of cooperation between the National Centre for Research (NCR) and the private-sector biotechnology company Vaccine Valley.
The country to date has been able to produce millions of doses of the Chinese Sinovac coronavirus vaccine while importing tens of millions of vaccines of all types.
Meanwhile, as per the data shared, a total of 39,629 doses of the COVID-19 vaccine were administered today, on February 7, 2022.
The situation of the COVID-19 virus in Egypt is not quite well, as the country recorded its highest tally of daily COVID-19 infections on Sunday.